Integrated BioPharma, Inc. And Fraunhofer CMB Announce Flu Vaccine Project
HILLSIDE, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Integrated BioPharma, Inc. and Fraunhofer USA Center for Molecular Biotechnology ("FCMB") announced today the successful validation of their proprietary, plant-based technology platform for the production of human therapeutic proteins and their further agreement to now engineer and produce vaccines against influenza using the validated platform.
The AIPwLV(TM) platform was developed for INB by FCMB over the last three years. It uses simple, non-genetically modified plants as a medium for the rapid, economical production of vaccine antigens. Unlike vaccine technologies currently in use, the AIPwLV(TM) platform enables practically limitless scalability of production of target antigens for vaccines against diseases such as influenza relatively quickly after identification of the active strain, thereby significantly increasing the availability of efficacious vaccines for large-scale inoculations.
"We expect the AIPwLV(TM) platform to significantly alleviate many of the problems affecting current vaccine technologies, particularly in the areas of safety, scalability, cost and time efficiency," said Dr. Vidadi Yusibov, Executive Director of FCMB.
"Now that the AIPwLV(TM) technology platform has been validated, we have engaged FCMB to develop specific vaccine products using the AIPwLV(TM) platform, the first of which is influenza vaccine," said E. Gerald Kay, Chairman of INB. "As we proceed with this product, we will be examining other product applications of the platform and possible licensing relationships for those who wish to use the AIPwLV(TM) platform for the production of vaccines and therapeutic proteins against other diseases," Mr. Kay added.
About Fraunhofer USA Center for Molecular Biotechnology
Fraunhofer USA Center for Molecular Biotechnology was established in July 2001 as a partnership between Fraunhofer Society in Germany and the State of Delaware. CMB is a non-profit organization that is part of Fraunhofer USA, Inc., incorporated in Rhode Island, with the license to conduct business in the state of Delaware. Fraunhofer USA, Inc. is headquartered in Plymouth, MI and has five Centers in the United States. CMB is located at the Delaware Technology Park in Newark, Delaware, and is a unique institution conducting research in the area of plant biotechnology, utilizing newly developed/developing cutting edge technologies to assist the diagnosis, prevention and treatment of human and animal diseases.
About Integrated BioPharma, Inc. (INB)
Integrated BioPharma, Inc. presently serves the varied needs of the health care industry through its Nutraceutical business, which creates, develops, manufactures and markets health products worldwide; its Biotechnology business, which uses its patented plant-based technology to produce vaccines and therapeutic antibodies; and its Pharmaceutical business, which operates contract research and cGMP manufacturing facilities. Further information is available at http://www.iBioPharma.com.
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
Integrated BioPharma, Inc.CONTACT: Dina Masi, CFO, or Jeffrey Leach, Investor Relations, both ofIntegrated BioPharma, Inc., at 1-888-319-6962, d.masi@ibiopharma.com
Web site: http://www.iBioPharma.com/